Benjamin F. Edwards & Company, Inc. Neurocrine Biosciences Inc Transaction History
Benjamin F. Edwards & Company, Inc.
- $5.69 Billion
- Q2 2024
A detailed history of Benjamin F. Edwards & Company, Inc. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Benjamin F. Edwards & Company, Inc. holds 226 shares of NBIX stock, worth $32,360. This represents 0.0% of its overall portfolio holdings.
Number of Shares
226
Previous 219
3.2%
Holding current value
$32,360
Previous $30,000
3.33%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding NBIX
# of Institutions
693Shares Held
102MCall Options Held
290KPut Options Held
214K-
Black Rock Inc. New York, NY14.2MShares$2.03 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.81MShares$1.4 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.57MShares$797 Million0.42% of portfolio
-
State Street Corp Boston, MA4.47MShares$640 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.09MShares$442 Million0.04% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $13.7B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...